Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Research context
Chong Kun Dang Pharmaceutical Corp appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Chong Kun Dang Pharmaceutical Corp is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 86.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Chong Kun Dang Pharmaceutical Corp's total revenue rose by 13.1% to $337B since the same quarter in the previous year.
Its net income has dropped by 29.5% to $11B since the same quarter in the previous year.
Finally, its free cash flow grew by 66.8% to $17B since the same quarter in the previous year.
Based on the above factors, Chong Kun Dang Pharmaceutical Corp gets an overall score of 3/5.